Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma

Lymphoma (follicular non-Hodgkin's) - rituximab: review decision - March 2011  information

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 84 KB)

Lymphoma (follicular non-Hodgkin's) - rituximab: review proposal - January 2011 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (MSWord 58 KB)

Appendix B: proposal paper presented to NICE's Guidance Executive

Follicular lymphoma - rituximab: final appraisal determination  information

Follicular lymphoma - rituximab: final appraisal determination

Follicular lymphoma - rituximab: final appraisal determination (PDF 95 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 57 KB)

Consultee and commentator comments on the ACD

Joint comment from British Society for Haematology and the Royal College of Physicians/Royal College of Pathologists Intercollegiate Committee in Haematology

Joint comment from British Society for Haematology and the Royal College of Physicians/Royal College of Pathologists Intercollegiate Committee in Haematology (PDF 25 KB)

Joint comment from NCRI Lymphoma Clinical Studies Group, Royal College of Physicians, the Royal College of Radiologists, the Joint Collegiate Council for Oncology and the Association of Cancer Physicians

Joint comment from NCRI Lymphoma Clinical Studies Group, Royal College of Physicians, the Royal College of Radiologists, the Joint Collegiate Council for Oncology and the Association of Cancer Physicians (PDF 49 KB)

Roche

Roche (PDF 1.16 MB)

Royal College of Nursing

Royal College of Nursing (PDF 22 KB)

Royal College of Pathologists

Royal College of Pathologists (PDF 110 KB)

Welsh Assembly Government

Welsh Assembly Government (PDF 63 KB)

Hancock

Follicular lymphoma - rituximab: Appraisal consultation 

Follicular lymphoma - rituximab: appraisal consultation document information

Follicular lymphoma - rituximab: Evaluation report

Expert written personal statements

Hancock

Hancock (PDF 81 KB)

Hamblin

Hamblin (PDF 19 KB)

Manufacturer submission

Roche response to clarification letter

Roche response to clarification letter (PDF 7.31 MB)

Clarification letter from NICE

Clarification letter from NICE (PDF 1.73 MB)

Roche Products Limited

Roche Products Limited (PDF 1007 KB)

Lymphoma Association

Lymphoma Association (PDF 86 KB)

EMEA documents

EMEA letter

EMEA letter (PDF 920 KB)

EMEA scientific discussion

EMEA scientific discussion (PDF 1.53 MB)

BCSH Guidelines

BCSH Guidelines (PDF 2.94 MB)

Evidence Review Group report

Supplemental Evidence Review Group report

Supplemental Evidence Review Group report (PDF 121 KB)

Lymphoma (follicular non-Hodgkin's) - rituximab: evidence review group report

Lymphoma (follicular non-Hodgkin's) - rituximab: evidence review group report (PDF 654 KB)

Pre-meeting briefing

Response to consultee and commentators comments on the draft Matrix and Scope

Follicular lymphoma - rituximab: final scope

Letter to consultees and commentators